[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100430177":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":33,"locations":38,"responsibleParty":59,"collaborators":62,"id":66,"slug":25,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":25,"enrollmentInfo":74,"targetDuration":25,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":25,"overallStatus":41,"whyStopped":25,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"University of Ulm","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Immunoadsorption","EXPERIMENTAL","3 cycles of immunoadsorption in week 1, 7, and 13 after randomization. One cycle consists of 5 sessions on 5 consecutive days with processing of the 2-fold plasma volume on the first day and the 2.5-fold plasma volume on consecutive days, using regenerative adsorbers (Therasorb, Miltenyi Biotec, Bergisch Gladbach)",[13],"Device: Immunoadsorption",{"label":15,"type":16,"description":17,"interventionNames":18},"Immunoglobulins","ACTIVE_COMPARATOR","5 cycles of intravenous immunoglobulins in week 1, 4, 7, 10, and 13 after randomization. The first cycle consists of 5 intravenous applications of immunoglobulins on 5 consecutive days in a dosage of 0.4 g per kg body weight per day. Subsequent cycles consist of 2 intravenous applications of immunoglobulins on 2 consecutive days in a dosage of 0.5 g per kg body weight per day.",[19],"Biological: Immunoglobulins",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","see arm\u002Fgroup description",[9],null,{"type":27,"name":15,"description":23,"armGroupLabels":28,"otherNames":25},"BIOLOGICAL",[15],[30],{"name":31,"affiliation":5,"role":32},"Johannes Dorst, Prof","PRINCIPAL_INVESTIGATOR",[34],{"name":31,"role":35,"phone":36,"phoneExt":25,"email":37},"CONTACT","+49 731 177 5285","johannes.dorst@uni-ulm.de",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Department of Neurology, University of Ulm","RECRUITING","Ulm","Baden-Wurttemberg","89081","Germany",{"type":47,"coordinates":48},"Point",[49,50],9.99155,48.39841,{"lat":50,"lon":49},[53,58],{"name":54,"role":35,"phone":55,"phoneExt":56,"email":57},"Albert C Ludolph, MD, Prof.","+49-731-177-","1200","albert.ludolph@rku.de",{"name":54,"role":32,"phone":25,"phoneExt":25,"email":25},{"type":32,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Albert Christian Ludolph, Prof.","Prof. Dr.",[63],{"name":64,"class":65},"Miltenyi Biomedicine GmbH","INDUSTRY","100430177",false,"NCT04881682","Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","IVITOC","Inclusion Criteria:\n\n* Diagnosis of possible, probable, or definite CIDP (typical or atypical) according to European Federation of Neurological Societies (EFNS) guidelines\n* Disease duration of 3 years or less\n* Age 18 years or above\n* Previous treatment with methyl-prednisolone and insufficient therapeutic response as judged by the treating physician, or contraindications against methyl-prednisolone, or clinically significant side effects under methyl-prednisolone therapy as judged by the treating physician\n\nExclusion Criteria:\n\n* Clinical or laboratory evidence of manifest systemic infection, i.e., C-reactive protein (CRP) above 20 mg\u002Fl, or evidence of nitrite-positive urinary tract infection\n* Intake of angiotensin converting enzyme inhibitor within 1 week before first treatment\n* immunoglobulin A deficiency\n* Other contraindications against immunoadsorption or intravenous immunoglobulins","ALL","18 Years",{"count":75,"type":76},20,"ESTIMATED","INTERVENTIONAL",[79],"PHASE2","This is a randomized controlled study evaluating safety and efficacy of repeated immunoadsorption versus immunoglobulins in steroid-refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).",[82],"CIDP","2026-04-30",{"date":85,"type":86},"2026-05-01","ACTUAL",{"date":88,"type":86},"2023-05-01",{"date":90,"type":76},"2028-03-01",{"name":5,"class":6},1]